The Administration for Children and Families (ACF), Office of Family Assistance (OFA), has had administrative responsibility for federal funding of programs that strengthen families through healthy marriage and relationship education and responsible fatherhood programming since 2006 through the Healthy Marriage (HM) and Responsible Fatherhood (RF) grant programs. ACF required the 2015 and 2020 cohorts of HMRF grant recipients to collect and report performance measures about program operations, s

Original title: “Submission for Office of Management and Budget Review; Healthy Marriage and Responsible Fatherhood Performance Measures and Additional Data Collection”

The Administration for Children and Families (ACF) is requesting public comments on a proposed information collection as part of the Safe Access for Victims' Economic Security (SAVES) Demonstration research on safety in the child support program. The SAVES Center, responsible for providing technical assistance and conducting evaluation for SAVES, will conduct one-time data collection activities with domestic violence (DV) survivors, advocates, and child support staff to understand their experien

Original title: “Submission for Office of Management and Budget Review; Safe Access for Victims' Economic Security, Data Collection for Safety in Child Support Program Research (New Collection)”

Referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “SRES 714: A resolution supporting the designation of May 10, 2026, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day".”

Placed on Senate Legislative Calendar under General Orders. Calendar No. 112.

Original title: “S 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026”

Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human Services.

Original title: “FDA taps Szarama as acting CBER director as Prasad’s tumultuous tenure ends”

Referred to the Committee on Agriculture, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7906: FOOD for Health Act”

Referred to the Subcommittee on Livestock, Dairy, and Poultry.

Original title: “HR 1376: Healthy Poultry Assistance and Indemnification Act of 2025”

The Food and Drug Administration (FDA) is classifying the phototherapy device for reducing the appearance of acute post-surgical incisions into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the phototherapy device for reducing the appearance of acute post-surgical incisions. We are taking this action because we have determined that classifying the device into class II wi

Original title: “Medical Devices; General and Plastic Surgery Devices; Classification of the Phototherapy Device for Reducing the Appearance of Acute Post-Surgical Incisions”

The Food and Drug Administration (FDA) is announcing its intent to exempt from premarket notification requirements certain class II clinical toxicology test system devices. FDA is publishing this notice and requesting public comment in accordance with procedures established by the 21st Century Cures Act. This notice does not represent FDA's final determination with respect to the devices included in this document. FDA will review any comments submitted within the 60-day comment period and will f

Original title: “Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments”

The Food and Drug Administration (FDA) is establishing a public docket entitled "Obesity and Drug Dosing: Clinical Pharmacology Considerations." The Agency is soliciting input from interested persons on assessing the effect of obesity on drug pharmacokinetics and pharmacodynamics during drug (including biological product) development. These assessments could potentially inform whether obesity impacts the safety and effectiveness of the drug and dosing recommendations for obese patients.

Original title: “Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments”

The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide. Additional bulk drug substances

Original title: “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act”

The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and other areas of interest.

Original title: “Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments”

This notice announces a public meeting to receive comments and recommendations (including data on which recommendations are based) on the appropriate basis for establishing payment amounts for new or substantially revised Healthcare Common Procedure Coding System codes being considered for Medicare payment under the Clinical Laboratory Fee Schedule for calendar year 2027. This meeting also provides a forum for those who submitted certain reconsideration requests regarding final determinations ma

Original title: “Medicare Program: Public Meeting Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 2027”

The Department of Health and Human Services (HHS) provides notice of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) using Urine and the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid.

Original title: “Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies”

FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.

Original title: “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 906: Peer to Peer Mental Health Support Act”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 4327: Securing America’s Drug Supply from Communist China Act”

While some analysts consider the return of advisory committees a positive sign for the FDA—and the biopharma industry more widely—others are keeping their optimism in check, waiting instead for more foundational changes at the regulator.

Original title: “FDA’s end to 9-month adcomm drought a 'narrow restart'”